{
  "docId": "019dd923-622c-750b-8b9b-7e7228555e88",
  "docSlug": "36c903ba19aa",
  "documentTitle": "Allergan, Inc. (AGN)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.70665085,
  "pageNumber": 35,
  "pageCount": 110,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list to define the company's R&D philosophy.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-7e7228555e88/35",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.09,
        "y": 0.15
      },
      "kind": "list",
      "text": "Focused on lower-risk, higher-reward programs: Line extensions and re-formulations, New indications and strengths for existing drugs, New branded generics, Prescription to OTC switches, High-probability development programs (Phase IIIs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "704e51ff-3365-47a9-b8e4-b3182b37e695",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.5,
        "x": 0.09,
        "y": 0.41
      },
      "kind": "list",
      "text": "Low, fixed-cost R&D Infrastructure: Outsource non-core R&D functions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "788111ae-f9d4-429d-b86f-d7829c260eb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.09,
        "y": 0.37
      },
      "kind": "list",
      "text": "No pre-set R&D spend as a percentage of revenue",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85b0c51c-617c-4aaa-9a63-8c6fc9b1ff20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.09,
        "y": 0.33
      },
      "kind": "list",
      "text": "No high-risk discovery R&D",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce38692a-d792-4c0c-9a4f-91794e59d7b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.82,
        "x": 0.09,
        "y": 0.08
      },
      "kind": "title",
      "text": "Valeant: Lower-Risk, Higher-Productivity R&D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b39625b-e134-4702-86a4-8cbdd8e48bcc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}